DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
FDA approved Zepbound for OSA с obesity in December 2024. Sleep study с AHI ≥15 + BMI ≥30 unlocks easier insurance PA than weight-loss-only indication.
December 2024 FDA approval expanded Zepbound's label к include OSA (obstructive sleep apnea) с obesity. This created a critical insurance pathway: many plans don't cover weight-loss-only GLP-1s but DO cover OSA treatment. PA criteria: documented OSA diagnosis (sleep study с AHI ≥15) plus BMI ≥30. SURMOUNT-OSA trial showed 50% reduction в AHI at 52 weeks. Insurance approval rate for OSA-with-obesity Zepbound is significantly higher than weight-loss Zepbound. If you snore: get a sleep study before any PA submission. If AHI ≥15: this is the cleanest path к Zepbound coverage.
Editorial answer reviewed by a board-certified clinician. Not medical advice. Coordinate treatment decisions with your prescriber.